Holen Sie sich die Stockscreener-App
47.37
0.55%
-0.26
Handel nachbörslich:
47.37
Schlusskurs vom Vortag:
$47.63
Offen:
$47.7
24-Stunden-Volumen:
608.67K
Relative Volume:
1.02
Marktkapitalisierung:
$3.24B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-11.99
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+17.84%
1M Leistung:
+19.20%
6M Leistung:
-11.56%
1J Leistung:
+5.27%
1-Tages-Spanne:
$46.75
$48.09
1-Wochen-Bereich:
$40.54
$48.09
52-Wochen-Spanne:
$37.77
$61.61
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
47.37 | 3.24B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (MRUS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks
La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab dans le carcinome épidermoïde de la tête et du cou positif PD-L1 positif en 1re ligne - GlobeNewswire Inc.
Merus Shares Are Up Today: What's Going On? - Benzinga
Merus Stock Surges on Breakthrough Therapy News - TipRanks
Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab -February 18, 2025 at 09:00 am EST - Marketscreener.com
Objective long/short (MRUS) Report - Stock Traders Daily
Petosemtamab granted Breakthrough Therapy designation by - GlobeNewswire
Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug - StockTitan
Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler - MarketBeat
Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials - MSN
Merus N.V.’s SWOT analysis: biotech firm’s stock poised for growth amid clinical trials - Investing.com Nigeria
BMO Capital Maintains Merus N.V. (MRUS) Outperform Recommendation - MSN
Guggenheim Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Receives Average Rating of “Buy” from Analysts - Defense World
Piper Sandler sets $84 target on Merus stock, cites drug potential - Investing.com Australia
FY2024 Earnings Forecast for Merus Issued By Leerink Partnrs - MarketBeat
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit -February 13, 2025 at 08:01 am EST - Marketscreener.com
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - The Manila Times
Revolutionary Cancer Treatment Updates: Merus CEO Takes Center Stage at Major Oncology Summit - StockTitan
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga India
Piper Sandler Initiates Merus at Overweight With $84 Price Target -February 13, 2025 at 07:36 am EST - Marketscreener.com
Piper Sandler sets $84 target on Merus stock, cites drug potential By Investing.com - Investing.com South Africa
Merus (NASDAQ:MRUS) Now Covered by Analysts at Wells Fargo & Company - MarketBeat
What is Leerink Partnrs’ Estimate for Merus FY2024 Earnings? - Defense World
Merus (NASDAQ:MRUS) Research Coverage Started at Wells Fargo & Company - Defense World
Q1 Earnings Estimate for Merus Issued By Leerink Partnrs - MarketBeat
Leerink Partnrs Comments on Merus’ Q1 Earnings (NASDAQ:MRUS) - Defense World
Wells Fargo sets $91 target on Merus stock, cites mCRC potential - MSN
Trend Tracker for (MRUS) - Stock Traders Daily
Wells Fargo sets $91 target on Merus stock, cites mCRC potential By Investing.com - Investing.com South Africa
Wells Fargo Initiates Merus at Overweight With $91 Price Target -February 07, 2025 at 08:40 am EST - Marketscreener.com
Merus Stock: Cancer Drug Study Results Spark Growth - sharewise
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewswire
Landmark Cancer Treatment: Merus's Bizengri Shows Promising Results for Untreatable Lung & Pancreatic Cancers - StockTitan
KBC Group NV Boosts Stake in Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
Analysts Set Merus (NASDAQ:MRUS) PT at $85.64 - MarketBeat
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff (NASDAQ:MRUS) - Seeking Alpha
Merus (NASDAQ:MRUS) Short Interest Down 15.5% in December - MarketBeat
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Will Merus' First Commercialized Drug, Bizengri, Drive Revenue Growth And Propel Stock Price? - RTTNews
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):